{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=37", "query": { "intervention": "Placebo Intravenous", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 2347, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=38&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=36&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:35:05.499Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02134951", "title": "Biomarker Assessment of Glutamatergic Target Engagement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy Controls" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 65, "start_date": "2014-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-08-17", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 3, "location_summary": "Sacramento, California • New Haven, Connecticut • New York, New York", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02134951" }, { "nct_id": "NCT00743769", "title": "A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myocardial Infarction", "Myocardial Ischemia" ], "interventions": [ { "name": "thymosin beta 4", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "RegeneRx Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 0, "start_date": "2008-04", "completion_date": "2017-01-01", "has_results": false, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743769" }, { "nct_id": "NCT05730283", "title": "Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ototoxicity, Drug-Induced" ], "interventions": [ { "name": "ORC-13661", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevin Winthrop", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 105, "start_date": "2025-06-02", "completion_date": "2028-02-29", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Manhasset", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05730283" }, { "nct_id": "NCT03182907", "title": "Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "Bezlotoxumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antibacterial drug treatment (ABD)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 148, "start_date": "2018-03-27", "completion_date": "2022-05-12", "has_results": true, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 21, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03182907" }, { "nct_id": "NCT02967692", "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Spartalizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 568, "start_date": "2017-02-17", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 12, "location_summary": "Encinitas, California • Orange, California • San Francisco, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02967692" }, { "nct_id": "NCT00520234", "title": "Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Invasive Candidiasis" ], "interventions": [ { "name": "Caspofungin", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mycoses Study Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2007-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-05-09", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520234" }, { "nct_id": "NCT02974010", "title": "Sequential Therapy for the Treatment of Severe Bipolar Depression.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bipolar Depression", "Suicidal Ideas", "Suicidal Ideation", "Suicide, Attempted" ], "interventions": [ { "name": "NRX-101 Oral Capsule", "type": "DRUG" }, { "name": "Lurasidone Oral Capsule", "type": "DRUG" }, { "name": "Ketamine Intravenous Infusion", "type": "DRUG" }, { "name": "Saline Solution Intravenous Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeuroRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 22, "start_date": "2018-01-15", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974010" }, { "nct_id": "NCT01018810", "title": "A Study for Adults With Plaque Psoriasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "LY2525623 Intravenous", "type": "DRUG" }, { "name": "LY2525623 Subcutaneous", "type": "DRUG" }, { "name": "Placebo Intravenous", "type": "DRUG" }, { "name": "Placebo Subcutaneous", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2009-12", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-07-29", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 20, "location_summary": "Mobile, Alabama • Peoria, Arizona • Hot Springs, Arkansas + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01018810" }, { "nct_id": "NCT07262060", "title": "Improving Preterm Kidney Outcomes With Caffeine", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Injury", "Pre-Term" ], "interventions": [ { "name": "Caffeine citrate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Hours", "maximum_age": "96 Hours", "sex": "ALL", "summary": "12 Hours to 96 Hours" }, "enrollment_count": 114, "start_date": "2026-05-28", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262060" }, { "nct_id": "NCT00891761", "title": "A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer", "Chemotherapy-Induced Nausea and Vomiting", "Nausea and Vomiting", "Solid Tumor Cancer" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "IV casopitant (placebo)", "type": "DRUG" }, { "name": "IV casopitant (active)", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-09", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2015-04-17", "last_synced_at": "2026-10-15T18:35:05.499Z", "location_count": 2, "location_summary": "Tampa, Florida • Robbinsdale, Minnesota", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Robbinsdale", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891761" } ] }